Nexplanon 68 MG implants
Ended Awarded
- Contract number
- SPE2DB26FQWLL
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,472
Award facts
- Contract value 100% obligated
- $3,471.55 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $3,471.55 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nexplanon 68 mg implants. The award, issued on October 27, 2025, is structured as a firm fixed-price delivery order with an ultimate completion date of November 18, 2025, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract awarded November 13, 2025, that positions the company as a critical pharmaceutical supplier for Department of Defense healthcare operations.
The PPV-G GEN V represents a component of the broader $30.3 billion acquisition strategy designed to supply a comprehensive range of pharmaceutical products, including branded and generic prescription medications, biologics, vaccines, and medical consumables to military healthcare facilities worldwide. DMS Pharmaceutical Group has demonstrated substantial federal contracting activity through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division, with its product portfolio encompassing specialty pharmaceuticals, oncology treatments, immunosuppressants, and medical devices supporting diverse clinical requirements across the military medical system. The indefinite delivery contract provides a 30-month base period with three 30-month option periods, establishing a long-term supply relationship through December 31, 2036.
Quick answers
Who was awarded contract SPE2DB26FQWLL?
SPE2DB26FQWLL was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DB26FQWLL worth?
The government has obligated $3,472 on SPE2DB26FQWLL.
Is contract SPE2DB26FQWLL an order under another contract?
Yes. SPE2DB26FQWLL is a delivery order under SPE2DB25D9321, an indefinite delivery contract.
Was contract SPE2DB26FQWLL competed?
The extent of competition for SPE2DB26FQWLL was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award